DEVELOPMENT AND OPTIMIZATION OF FAST-DISSOLVING BILASTINE SUBLINGUAL FILMS USING STATISTICAL DESIGN
DOI:
https://doi.org/10.22159/ijap.2025v17i2.53250Keywords:
Bilastine, Fast dissolving sublingual film, HP-β-CD inclusion complex, Design of experiments, Full factorial designAbstract
Objective: This present research study was undertaken with the objective of formulating a fast-dissolving sublingual film of pre-solubilized bilastine. The aim was to overcome the need for acidic gastric media for the solubilization of bilastine, eliminating the concern of reduced bioavailability due to interaction with food and providing a faster onset of action, owing to the high vascularity in the sublingual region.
Methods: Solubility enhancement of bilastine was achieved by inclusion-complex formation of bilastine and Hydroxypropyl Beta-Cyclodextrin (2-HP-β-CD). Fast-dissolving sublingual films were formulated by incorporating bilastine-2-HP-β-CD in the film prepared using the solvent casting method, wherein the sublingual film formulation was optimized using the Design of Experiments (DoE) approach by applying 23 factorial designs. The optimized sublingual film was evaluated.
Results: Evaluation tests revealed that the optimized sublingual film possessed adequate flexibility and tensile strength. It exhibited a faster in vitro drug release of 97.41%, which was achieved in 7 min compared to a 35.77% in vitro drug release demonstrated by the pure drug-containing film. This indicates a 2.7-fold enhancement in dissolution with an average disintegration time of 41.66±0.57 s. The ex vivo permeation studies showed an in vitro drug release of 95.21%, indicating good permeation.
Conclusion: Based on the research findings obtained, it is possible to conclude that the developed quick-dissolving sublingual film of bilastine possessed an enhanced dissolution profile and exhibited a faster onset of action. These results demonstrate the potential to avoid food interactions and improve patient compliance. Incorporating bilastine into sublingual films offers superior benefits over conventional oral formulations, such as circumventing hepatic first-pass metabolism and providing quick relief. Thus, it serves as a potential alternative for the treatment of chronic urticaria and allergic rhinitis.
References
Sachdeva S, Gupta V, Amin SS, Tahseen M. Chronic urticaria. Indian J Dermatol. 2011 Nov;56(6):622-8. doi: 10.4103/0019-5154.91817, PMID 22345759.
Dias GA, Pires GV, Valle SO, Dortas SD Junior, Levy S, França AT. Impact of chronic urticaria on the quality of life of patients followed up at a university hospital. An Bras Dermatol. 2016 Nov-Dec;91(6):754-9. doi: 10.1590/abd1806-4841.20165071, PMID 28099596.
Ridolo E, Montagni M, Bonzano L, Incorvaia C, Canonica GW. Bilastine: new insight into antihistamine treatment. Clin Mol Allergy. 2015 Apr 15;13(1):1. doi: 10.1186/s12948-015-0008-x, PMID 25878559.
Carter NJ. Bilastine: in allergic rhinitis and urticaria. Drugs. 2012 Jun 18;72(9):1257-69. doi: 10.2165/11209310-000000000-00000, PMID 22686617.
Church MK, Tiongco Recto M, Ridolo E, Novak Z. Bilastine: a lifetime companion for the treatment of allergies. Curr Med Res Opin. 2020 Mar;36(3):445-54. doi: 10.1080/03007995.2019.1681134, PMID 31612732.
Church MK. Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Expert Opin Drug Saf. 2011 Sep;10(5):779-93. doi: 10.1517/14740338.2011.604029, PMID 21831011.
Bhalani DV, Nutan B, Kumar A, Singh Chandel AK. Bioavailability enhancement techniques for poorly aqueous soluble drugs and therapeutics. Biomedicines. 2022 Aug 23;10(9):2055. doi: 10.3390/biomedicines10092055, PMID 36140156.
Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. ISRN Pharm. 2012;2012:195727. doi: 10.5402/2012/195727, PMID 22830056.
Alhamhoom Y, Sharma A, Nanjappa SH, Kumar A, Alshishani A, Ahmed MM. Development and evaluation of solid dispersion based sublingual films of nisoldipine. Pharmaceuticals (Basel). 2023 Nov 9;16(11):1589. doi: 10.3390/ph16111589, PMID 38004454.
Yusuf A, Almotairy AR, Henidi H, Alshehri OY, Aldughaim MS. Nanoparticles as drug delivery systems: a review of the implication of nanoparticles physicochemical properties on responses in biological systems. Polymers (Basel). 2023 Mar 23;15(7):1596. doi: 10.3390/polym15071596, PMID 37050210.
Thapa RK, Kim JO. Nanomedicine based commercial formulations: current developments and future prospects. J Pharm Investig. 2023;53(1):19-33. doi: 10.1007/s40005-022-00607-6, PMID 36568502.
Shah JN, Shah KN, Mehta TA. Hydroxy propyl β-cyclodextrin complexation of promethazine hydrochloride for the formulation of fast dissolving sublingual film: in vitro and in vivo evaluation. J Pharm Investig. 2015 Feb 1;45(1):91-9. doi: 10.1007/s40005-014-0150-3.
Ulucan Karnak F, Kuru CI. Advantages of nanodrug targeting than conventional dosage system. Nanotechnology for Drug Delivery and Pharmaceuticals; 2023. p. 295-310. doi: 10.1016/B978-0-323-95325-2.00003-1.
Mary DC ruz CE, Bhide PJ, Kumar L, Shirodkar RK. Novel nano spanlastic carrier system for buccal delivery of lacidipine. J Drug Deliv Sci Technol. 2022 Feb;68:103061. doi: 10.1016/j.jddst.2021.103061.
Singh H, Singla YP, Narang RS, Pandita D, Singh S, Narang JK. Frovatriptan loaded hydroxy propyl methyl cellulose/treated chitosan based composite fast dissolving sublingual films for management of migraine. J Drug Deliv Sci Technol. 2018 Oct;47:230-9. doi: 10.1016/j.jddst.2018.06.018.
Ghosh A, Biswas S, Ghosh T. Preparation and evaluation of silymarin β-cyclodextrin molecular inclusion complexes. J Young Pharm. 2011 Jul;3(3):205-10. doi: 10.4103/0975-1483.83759, PMID 21897659.
Dinge A, Nagarsenker M. Formulation and evaluation of fast dissolving films for delivery of triclosan to the oral cavity. AAPS Pharm Sci Tech. 2008;9(2):349-56. doi: 10.1208/s12249-008-9047-7, PMID 18431674.
Farooqui P, Gude R. Formulation development and optimisation of fast dissolving buccal films loaded glimepiride solid dispersion with enhanced dissolution profile using central composite design. Int J Pharm Pharm Sci. 2023 Jun 1;15(6):35-54. doi: 10.22159/ijpps.2023v15i6.47992.
El Said IA, Aboelwafa AA, El Gazayerly ON. Optimization of taste masked dapoxetine oral thin films using factorial design: in vitro and in vivo evaluation. Pharm Dev Technol. 2021 Jun;26(5):522-38. doi: 10.1080/10837450.2021.1894445, PMID 33663316.
Al Nemrawi NK, Dave RH. Formulation and characterization of acetaminophen nanoparticles in orally disintegrating films. Drug Deliv. 2016;23(2):540-9. doi: 10.3109/10717544.2014.936987, PMID 25013958.
Chavan DU, Marques SM, Bhide PJ, Kumar L, Shirodkar RK. Rapidly dissolving felodipine nanoparticle strips formulation using design of experiment and characterisation. J Drug Deliv Sci Technol. 2020 Dec;60:102053. doi: 10.1016/j.jddst.2020.102053.
Chonkar AD, Bhagawati ST, Udupa N. An overview on fast dissolving oral films. Asian J Pharm Technol. 2015;5(3):129. doi: 10.5958/2231-5713.2015.00020.3.
Koland M, Sandeep V, Charyulu N. Fast dissolving sublingual films of ondansetron hydrochloride: effect of additives on in vitro drug release and mucosal permeation. J Young Pharm. 2010 Jul;2(3):216-22. doi: 10.4103/0975-1483.66790, PMID 21042474.
Londhe V, Shirsat R. Formulation and characterization of fast dissolving sublingual film of iloperidone using box behnken design for enhancement of oral bioavailability. AAPS Pharm Sci Tech. 2018 Apr;19(3):1392-400. doi: 10.1208/s12249-018-0954-y, PMID 29396734.
Rekha SM, Shaheda Sultana SK, Mahathi K, Parveen P, Prathima B, Seetha Devi A. Formulation and evaluation of fast dissolving buccal film containing isradipine solid dispersion. American Journal of PharmTech Res. 2015;5(2).
Kumar GP, Phani AR, Prasad RG, Sanganal JS, Manali N, Gupta R. Polyvinylpyrrolidone oral films of enrofloxacin: film characterization and drug release. Int J Pharm. 2014 Aug 25;471(1-2):146-52. doi: 10.1016/j.ijpharm.2014.05.033, PMID 24858388.
Bharti K, Mittal P, Mishra B. Formulation and characterization of fast dissolving oral films containing buspirone hydrochloride nanoparticles using design of experiment. J Drug Deliv Sci Technol. 2019 Feb;49:420-32. doi: 10.1016/j.jddst.2018.12.013.
Dhimmar B, Pokale R, Rahamathulla M, Hani U, Alshahrani MY, Alshehri S. Newfangled topical film forming solution for facilitated antifungal therapy: design development characterization and in vitro evaluation. Polymers (Basel). 2023 Feb 17;15(4):1003. doi: 10.3390/polym15041003, PMID 36850286.
Torgal T, Borkar S, Bhide P, Arondekar A. Formulation development and evaluation of fast dissolving films of ebastine. Int J Curr Pharm Sci. 2020 Sep 17;12(5):111-5. doi: 10.22159/ijcpr.2020v12i5.39782.
Takeuchi Y, Kawamoto M, Tahara K, Takeuchi H. Design of a new disintegration test system for the evaluation of orally disintegrating films. Int J Pharm. 2018 Dec 20;553(1-2):281-9. doi: 10.1016/j.ijpharm.2018.10.049, PMID 30366069.
Pinto S, Pintado ME, Sarmento B. In vivo ex vivo and in vitro assessment of buccal permeation of drugs from delivery systems. Expert Opin Drug Deliv. 2020 Jan;17(1):33-48. doi: 10.1080/17425247.2020.1699913, PMID 31786958.
Kulkarni U, Mahalingam R, Pather I, LI X, Jasti B. Porcine buccal mucosa as in vitro model: effect of biological and experimental variables. J Pharm Sci. 2010 Mar;99(3):1265-77. doi: 10.1002/jps.21907, PMID 19739112.
Published
How to Cite
Issue
Section
Copyright (c) 2025 JASMINE LIBERATA FERNANDES, PRASHANT JIVAJI BHIDE, SHAILA ANGELA LEWIS
This work is licensed under a Creative Commons Attribution 4.0 International License.
